Clinical trials located in

Ludwigsburg

Ludwigsburg city is located in Germany. Currently, 6 clinical trials are being conducted in this city.

Ludwigsburg, nestled in Germany, is renowned for its baroque architecture, notably the Ludwigsburg Palace, which boasts 452 rooms. Established in the early 18th century, this city thrives on its rich history, including the Fairy-Tale Garden that captivates with its magical themes. Ludwigsburg also celebrates the Baroque Christmas Market, blending traditional charm with festive spirit. The city’s commitment to culture is evident in its hosting of the Ludwigsburg Festival, showcasing international music and arts. Additionally, Ludwigsburg is a hub for education and innovation, home to renowned institutions and industries.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing Durvalumab alongside radiotherapy for lung cancer patients

    This study focuses on elderly or frail Stage III lung cancer patients who cannot undergo chemotherapy. It tests the combination of Durvalumab, an immunotherapy drug, with two types of radiotherapy: standard and a shorter, concentrated method. The aim is to evaluate the treatment’s safety, effectiveness, and its impact on the immune system. Monitoring includes checking for pneumonitis, tumor size, disease spread, and patient quality of life every 3 months. The study seeks to determine if this combination can control cancer growth and improve patient well-being.

    • Durvalumab
  • Study of Dato-DXd and durvalumab in persistent triple-negative breast cancer

    This trial is about testing a combination of new treatments for triple-negative breast cancer which hasn’t fully responded to the first line of treatment. The new treatment includes a drug called Dato-DXd and a known drug called Durvalumab, both administered individually, or as a combination. This is compared to an already established treatment recommended by the doctor. The researchers are mainly interested in delaying the return of the cancer, and if the new drug with or without Durvalumab does a better job at this than the doctor-recommended treatment. Along with this main goal, the trial will also monitor how these treatments affect patients’ routine activities, their well-being, their levels of fatigue, the amount of Dato-DXd and related components present in the body, and any side effects and potential risks associated with these treatments.

    • Dato-DXd
    • Pembrolizumab
    • Capecitabine
    • Durvalumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.